Search Results - "Kushner, B H"

Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants by Gerald, W L, Ladanyi, M, de Alava, E, Cuatrecasas, M, Kushner, B H, LaQuaglia, M P, Rosai, J

“…Intense investigation has reshaped concepts about undifferentiated tumors occurring in young people (small round-cell tumors). Tumors associated with…”
Get more information

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma by Kushner, B H, Modak, S, Kramer, K, Basu, E M, Roberts, S S, Cheung, N-KV

“…5-day/5-drug (5D/5D) is a novel high-dose regimen administered with autologous hematopoietic SCT (HSCT). It was designed to maximize cytoreduction via high…”
Get full text

Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy by Kushner, B H, LaQuaglia, M P, Wollner, N, Meyers, P A, Lindsley, K L, Ghavimi, F, Merchant, T E, Boulad, F, Cheung, N K, Bonilla, M A, Crouch, G, Kelleher, Jr, J F, Steinherz, P G, Gerald, W L

“…To test intensive alkylator-based therapy in desmoplastic small round-cell tumor (DSRCT). Patients received the P6 protocol, which has seven courses of…”
Get more information

Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system by KUSHNER, B. H, KRAMER, K, MODAK, S, KERNAN, N. A, REICH, L. M, DANIS, K, CHEUNG, N.-K. V

“…We report on a three-drug myeloablative regimen designed to consolidate remission and to prevent central nervous system (CNS) relapse of high-risk…”
Get full text

How Effective Is Dose-Intensive/Myeloablative Therapy Against Ewing’s Sarcoma/Primitive Neuroectodermal Tumor Metastatic to Bone or Bone Marrow? The Memorial Sloan-Kettering Experience and a Literature Review by KUSHNER, Brian H, MEYERS, Paul A

“…Attempts to improve outcomes of patients with Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) metastatic to bone/bone marrow (BM) have focused on…”
Get full text

Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients by KUSHNER, Brian H, YEUNG, Henry W. D, LARSON, Steven M, KRAMER, Kim, CHEUNG, Nai-Kong V

“…Although positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18)F-FDG) has a major impact on the treatment of adult cancer, the reported…”
Get full text

Optimal Repeated Measurements Designs: The Linear Optimality Equations by Kushner, H. B.

“…In approximate design theory, necessary and sufficient conditions that a repeated measurements design be universally optimal are given as linear equations…”
Get full text

Optimal and Efficient Repeated-Measurements Designs for Uncorrelated Observations by Kushner, H. B.

“…In repeated measurements (crossover or changeover) designs, experimental subjects (units) are repeatedly exposed to treatments. Effects of treatments from one…”
Get full text

Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery by KUSHNER, Brian H, WOLDEN, Suzanne, LAQUAGLIA, Michael P, KRAMER, Kim, VERBEL, David, HELLER, Glenn, CHEUNG, Nai-Kong V

“…To assess prognostic factors for local control in high-risk neuroblastoma patients treated with hyperfractionated 21-Gy total dose to consolidate remission…”
Get full text

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review by Kushner, B H, Cheung, N K, Kramer, K, Heller, G, Jhanwar, S C

“…To assess treatment-related myelodysplasia/leukemia (t-AML) in neuroblastoma patients by a review of the Memorial Sloan-Kettering Cancer Center (MSKCC) data…”
Get more information

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age by Kushner, B H, LaQuaglia, M P, Bonilla, M A, Lindsley, K, Rosenfield, N, Yeh, S, Eddy, J, Gerald, W L, Heller, G, Cheung, N K

“…To test the efficacy of a protocol for poor-risk neuroblastoma that builds on the following: (1) our favorable previously reported results with dose-intensive…”
Get more information

Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? by Cheung, N K, Heller, G, Kushner, B H, Liu, C, Cheung, I Y

“…To measure the sensitivity of histologic examination in detecting metastatic solid tumor in bone marrow. A total of 145 patients with stage 4 neuroblastoma…”
Get more information

High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors by Kushner, B H, Heller, G, Cheung, N K, Wollner, N, Kramer, K, Bajorin, D, Polyak, T, Meyers, P A

“…To help fill the gap in knowledge about the risk of leukemia from repetitive high-dose use of alkylating agents and topoisomerase-II inhibitors in young…”
Get more information

Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults by Kushner, B H, Meyers, P A, Gerald, W L, Healey, J H, La Quaglia, M P, Boland, P, Wollner, N, Casper, E S, Aledo, A, Heller, G

“…To improve the prognosis of patients with poor-risk peripheral primitive neuroectodermal tumors (pPNETs; including peripheral neuroepithelioma and Ewing's…”
Get more information

Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy by Kushner, B H, Cheung, N K, LaQuaglia, M P, Ambros, P F, Ambros, I M, Bonilla, M A, Gerald, W L, Ladanyi, M, Gilbert, F, Rosenfield, N S, Yeh, S D

“…To test the hypothesis that cytotoxic therapy is not needed at diagnosis to assure the survival of most patients with non-stage 4 neuroblastoma. Patients with…”
Get more information

GM-CSF Enhances 3F8 Monoclonal Antibody-Dependent Cellular Cytotoxicity Against Human Melanoma and Neuroblastoma by Kushner, Brian H., Cheung, Nai-Kong V.

“…3F8 is a murine monoclonal lgG3 antibody specific for the tumor-associated antigen ganglioside GD2. Previous in vitro studies suggest that tumor regressions…”
Get full text

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults by KUSHNER, B. H, CHEUNG, N.-Kv, KRAMER, K, DUNKEL, I. J, CALLEJA, E, BOULAD, F

“…Topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms, may potentiate cytotoxicity of alkylators, has good…”
Get full text

Local control with multimodality therapy for stage 4 neuroblastoma by Wolden, S L, Gollamudi, S V, Kushner, B H, LaQuaglia, M, Kramer, K, Rosen, N, Abramson, S, Cheung, N V

“…To evaluate the efficacy of 21 Gy hyperfractionated radiotherapy for local control in conjunction with surgery and intensive systemic therapy for patients with…”
Get more information

Absolute requirement of CD11/CD18 adhesion molecules, FcRII, and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity by KUSHNER, B. H, CHEUNG, N.-K. V

“…We have previously shown that 3F8, a murine IgG3, monoclonal antibody (MoAb) specific for the ganglioside GD2, mediates tumor cell kill in vitro and in vivo…”
Get full text

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study by Cheung, N K, Kushner, B H, Yeh, S D, Larson, S M

“…3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had…”
Get more information